be
2023: Scale Expansion Period (Leveraging RCEP + Product Upgrading)​

2023: Scale Expansion Period (Leveraging RCEP + Product Upgrading)​

1. Strategic Cooperation Achievements
Signed a Customized Chiral Intermediate Agreement with Germany's Merck Group: Supplied enantiopure (R)-phenylglycinol and (S)-lactic acid derivatives for Merck's cardiovascular drug production, with an annual supply volume of 3,800 tons and a contract value of 28 million US dollars. The products feature enantiomeric excess (ee) ≥ 99.5% and impurity content 1%, becoming Merck's core alternative to Japanese suppliers for this product category.
Participated in Thailand's Pharmaceutical Park Project: Provided key intermediates (including piperazine derivatives and imidazole compounds) for Thailand's National Pharmaceutical Manufacturing Center, and exported green synthesis technology. The project has a contract value of 180 million US dollars with an annual supply volume of 1,800 tons, supporting Thailand's local production of anti-diabetic and anti-hypertensive drugs.


2. Export Scale Cases
Explosive Export Growth in the RCEP Region: Taking advantage of RCEP's tariff reduction on pharmaceutical products (average tariff reduction from 8% to 0.5%), exported benzene series intermediates, heterocyclic compounds and other products to Australia, New Zealand and 8 ASEAN countries, with an annual export volume of 18,000 tons and an export value of 320 million RMB, a year-on-year increase of 65%. Among them, export growth to Malaysia and the Philippines exceeded 75%.
Export of High-purity API Intermediates to South America: For the first time exported cefazolin sodium intermediates and amoxicillin side chains to Brazil and Argentina, with an annual export volume of 3,000 tons and an export value of 47 million RMB. It has become a preferred import substitution brand in South America's API production industry, with market share increasing from 0 to 6%.


3. Market Breakthrough Cases
Leading Quinolone Intermediates in Southeast Asia: Developed norfloxacin intermediates (1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-piperazin-1-yl-3-quinolinecarboxylic acid) tailored to the region's anti-infective drug demand, capturing 20% of the market in Vietnam and Indonesia with annual sales of 98 million RMB, a year-on-year growth of 90%. Cooperation clients include Daiichi Sankyo Vietnam and Kalbe Farma Indonesia.
RCEP Cross-border Pharmaceutical Logistics Optimization: Launched a dedicated cold-chain logistics route via Guangxi-Beibu Gulf Port to Southeast Asia, transporting temperature-sensitive intermediates (such as peptide intermediates) with an annual shipment volume of 10,000 tons, a 105% increase compared with 2022. Logistics costs were reduced by 18% and on-time delivery rate reached 99%.



Glutathione Gains Global Attention as Science, Wellness, and Regulation Converge
Dec 30, 25
Glutathione Gains Global Attention as Science, Wellness, and Regulation Converge

Glutathione, often referred to as the body’s “master antioxidant,” has moved from relative obscurity in medical textbooks to the center of global discussion in health, wellness, and biotechnology. Once known primarily to researchers and clinicians, this naturally occurring molecule is now widely discussed in contexts ranging from chronic disease research to skincare trends and dietary supplements. As interest continues to grow, scientists, regulators, and consumers alike are reexamining what glutathione is, what it can do, and how it should be used responsibly.

Dianabol (Methandienone) Remains at the Center of Global Debate on Performance-Enhancing Drugs
Oct 17, 25
Dianabol (Methandienone) Remains at the Center of Global Debate on Performance-Enhancing Drugs

With the deepening implementation of the "Made in China 2025" strategy and the rapid advancement of high-end equipment manufacturing, China's coupling industry is accelerating its transformation toward intelligent and precision-oriented development. 

Growing Concerns Surround the Illicit Market for Anabolic Steroids Oil Dianabol
Oct 17, 25
Growing Concerns Surround the Illicit Market for Anabolic Steroids Oil Dianabol

The global conversation around performance-enhancing drugs has intensified once again as anabolic steroids, particularly products marketed as Oil Dianabol, continue to surface in illegal markets. Dianabol, scientifically known as methandrostenolone, is one of the most well-known anabolic steroids in bodybuilding history. Originally developed in the mid-20th century for medical use, it has long since become controversial due to widespread misuse, health risks, and regulatory crackdowns.

Contact Us
Contact Us Let's TalkYour Any Query
Subscribe For Newsletter!
Your Email...

If you are interested in our products, you can choose to leave your information here, and we will be in touch with you shortly.